Table 1.
HIV-1 Protein- or Peptide-Specific Antibodies Detected in Plasma Using ELISA
| |
Laboratory A |
Laboratory B |
Laboratory C |
Laboratory D |
Laboratory E |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Clade B gp120 |
Clade C HIV lystate |
gp41 peptide 1 |
gp41 peptide 2 |
Clade C gp120 |
Clade B gp41 |
Clade C gp120 |
||||||
| |
IgG |
IgA |
IgG |
IgA |
IgG |
IgA |
IgG |
IgG |
IgA |
IgG |
IgA |
IgG |
IgA |
| (% of total) | (μg/ml) | (reciprocal endpoint titer) | (mOD/min) | (reciprocal endpoint titer) | |||||||||
| HIV-1 infected subjects | |||||||||||||
| 1 | 0.47 | 0.21 | 2,352.2 | 18.3 | > 4,096 | – | – | 523.9 | 306.8 | >640 | >640 | >640 | >640 |
| 2 | 1.07 | 0.41 | 7,198.7 | 51.4 | > 4,096 | – | >4,096 | 542.7 | 76.9 | >640 | >640 | >640 | >640 |
| 3 | 1.69 | 0.04 | 707.8 | – | > 4,096 | – | 1,024 | 492.8 | 70.8 | >640 | >640 | >640 | >640 |
| 4 | 0.39 | 0.07 | 5,652.0 | 6.4 | > 4,096 | – | – | 632.9 | 127.6 | >640 | >640 | >640 | >640 |
| 5 | 1.34 | – | 11,315.6 | 159.8 | > 4,096 | – | 512 | 558.2 | – | >640 | >640 | >640 | >640 |
| 6 | 1.72 | 0.24 | 757.2 | 1.2 | > 4,096 | 512 | – | 634.7 | 365.4 | >640 | >640 | >640 | >640 |
| 7 | 1.43 | 0.04 | 2,966.6 | 9.3 | > 4,096 | – | – | 598.8 | 18.9 | >640 | >640 | >640 | >640 |
| 8 | 3.24 | 0.07 | 1,240.4 | 3.1 | > 4,096 | – | – | 599.5 | 25.9 | >640 | >640 | >640 | >640 |
| 9 | 1.36 | – | 701.2 | – | > 4,096 | – | – | 829.5 | 17.5 | >640 | >640 | >640 | >640 |
| 10 | 1.49 | 0.06 | 4,792.2 | 2.3 | > 4,096 | – | – | 890.2 | 111.7 | >640 | >640 | >640 | >640 |
| 11 | 1.26 | 0.03 | 1,406.9 | 1.2 | > 4,096 | – | – | 582.6 | 334.4 | >640 | >640 | >640 | >640 |
| 12 | 1.34 | – | 1,542.4 | 1.2 | > 4,096 | – | – | 454.8 | – | >640 | nd | >640 | nd |
| 13 | 1.83 | – | 7,566.2 | 6.9 | > 4,096 | – | – | 520.9 | 15.0 | >640 | >640 | >640 | >640 |
| 14 | 1.28 | 0.24 | 2,062.4 | 0.8 | > 4,096 | – | >4,096 | 757.8 | 101.6 | >640 | >640 | >640 | >640 |
| 15 | 3.10 | 0.25 | 11,987.1 | 155.4 | > 4,096 | – | >4,096 | 485.5 | 159.4 | >640 | >640 | >640 | >640 |
| 16 | 0.95 | – | 238.1 | – | > 4,096 | – | – | 636.7 | 11.4 | >640 | nd | >640 | >640 |
| 17 | 1.95 | 0.28 | 18,561.1 | 81.2 | > 4,096 | >4,096 | – | 733.6 | 583.3 | >640 | >640 | >640 | >640 |
| 18 | 1.28 | 0.12 | 330.5 | – | > 4,096 | – | – | 654.3 | 55.0 | >640 | >640 | >640 | >640 |
| 19 | 2.32 | – | 2,152.6 | – | > 4,096 | – | >4,096 | 752.7 | 26.3 | >640 | 640 | >640 | >640 |
| 20 | 2.46 | – | 391.0 | – | > 4,096 | – | – | 629.2 | 13.6 | >640 | nd | >640 | >640 |
| 21 | 0.40 | 0.10 | 4,089.0 | 16.8 | > 4,096 | – | – | 642.8 | 35.1 | >640 | >640 | >640 | >640 |
| 22 | 1.79 | – | 6,420.4 | 8.0 | > 4,096 | – | – | 537.3 | 32.1 | >640 | >640 | >640 | >640 |
| 23 | 1.16 | 0.26 | 1,149.7 | – | > 4,096 | – | – | 627.1 | 26.1 | >640 | >640 | >640 | >640 |
| 24 | 1.66 | – | 2,852.9 | 22.9 | > 4,096 | – | – | 676.2 | 112.5 | >640 | 640 | >640 | >640 |
| 25 | 1.12 | – | 852.0 | – | > 4,096 | – | 4,096 | 829.7 | – | >640 | >640 | >640 | >640 |
| 26 | 1.39 | 0.19 | 1,146.7 | 1.2 | > 4,096 | – | 128 | 869.3 | 28.5 | >640 | >640 | >640 | >640 |
| HEPSN subjects | |||||||||||||
| 1 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 2 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 3 | – | – | 1.4 | – | – | – | – | – | – | – | – | – | – |
| 4 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 5 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 6 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 7 | – | – | – | – | – | – | – | – | – | >640 | 20 | – | – |
| 8 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 9 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 10 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 11 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 12 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 13 | – | – | – | – | 512 | – | 128 | – | – | – | – | – | – |
| 14 | – | – | – | – | – | – | – | – | – | – | 40 | – | – |
| 15 | – | – | – | – | – | – | 512 | 35.8 | – | – | – | – | – |
| 16 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 17 | – | – | – | – | – | – | – | 16.2 | – | – | – | – | – |
| 18 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 19 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 20 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 21 | – | – | – | – | 1024 | – | 512 | – | – | – | 20 | – | – |
| 22 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 23 | – | – | – | – | 512 | – | – | – | – | – | – | – | – |
| 24 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 25 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 26 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 27 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 28 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 29 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 30 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 31 | – | – | – | – | – | – | 256 | – | – | – | – | – | – |
| 32 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 33 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 34 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 35 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 36 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 37 | – | – | – | – | – | – | – | – | – | – | 640 | – | – |
| 38 | – | – | – | – | – | – | 256 | – | – | – | – | – | – |
| 39 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 40 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 41 | – | – | – | – | – | – | – | 49.3 | – | – | – | – | – |
Values presented are for specimens that were reported to contain significant anti-HIV-1 antibody. Dashes denote the samples which were negative. In Laboratory B, 0/41 HEPSN plasma tested positive for gp41-specific IgA using an ELISA with gp41MN capture antigen (not shown). nd: not done.